Oct. 4 at 1:52 PM
$COST $NVO $HIMS
Costco’s decision to sell Wegovy at a discounted price—through its partnership with Novo Nordisk—has hurt Hims & Hers (
$HIMS) stock. The move gives consumers access to the official GLP-1 drug, undercutting HIMS’ business model that relied on selling compounded or telehealth-prescribed alternatives. With the FDA ending emergency compounding allowances and Novo ending its collaboration with HIMS, investors now expect tighter regulation, margin pressure, and loss of market share—sending HIMS shares lower.
